Axonics, Inc. (AXNX) Stock Analysis

Axonics, Inc. (AXNX) Healthcare & Pipeline Overview

Axonics, Inc. is a medical technology company specializing in sacral neuromodulation (SNM) systems for bladder and bowel dysfunction. Its rechargeable technology and Bulkamid product offer alternatives to traditional treatments, positioning it as an innovator in the neuromodulation market with a growing international presence.

What Is the Investment Thesis for AXNX?

Axonics, Inc. presents a notable research candidate due to its innovative SNM technology and growing market presence. The company's rechargeable SNM system offers a competitive advantage over traditional non-rechargeable devices. Key value drivers include continued market penetration in the United States and expansion into international markets. Growth catalysts include increasing awareness of SNM therapy and positive clinical outcomes. Potential risks include competition from established medical device companies and regulatory hurdles. The company's gross margin of 74.9% indicates strong pricing power and efficient operations. Investors should monitor the company's ability to maintain its growth trajectory and manage its operating expenses.

Based on FMP financials and quantitative analysis

AXNX Key Highlights

Market capitalization of $3.63B reflects investor confidence in Axonics' growth potential.

• Gross margin of 74.9% demonstrates strong profitability on sales.
• The company's focus on sacral neuromodulation (SNM) addresses a significant unmet need in the treatment of bladder and bowel dysfunction.
• Axonics' rechargeable SNM system offers a competitive advantage over traditional non-rechargeable devices.
• The company's international expansion strategy provides opportunities for revenue growth in new markets.

Who Are AXNX's Competitors?

AXNX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are AXNX's Key Strengths?

Innovative rechargeable SNM system.

• Strong gross margin of 74.9%.
• Direct salesforce and distribution network.
• Focus on a growing market with unmet needs.

What Are AXNX's Weaknesses?

Negative profit margin of -1.7%.

• Reliance on a limited number of products.
• Competition from established medical device companies.
• Dependence on regulatory approvals.

What Could Drive AXNX Stock Higher?

Continued market penetration in the United States for the r-SNM system.

• Expansion into new international markets, including Asia-Pacific and Latin America.
• Increasing awareness of SNM therapy among patients and healthcare providers.
• Potential regulatory approvals for new applications of SNM technology.
• Positive clinical trial results for new SNM products.

What Are the Key Risks for AXNX?

Negative return on equity (-1.0%) — the business is not currently generating profit on shareholder capital.

• Insider selling — insiders were net sellers of roughly $8.9M recently.
• Competition from established medical device companies with greater resources.
• Regulatory hurdles and reimbursement challenges for new products.
• Product liability claims related to SNM devices.
• Economic downturns affecting healthcare spending.
• Dependence on key personnel and suppliers.

What Are the Growth Opportunities for AXNX?

• Expansion into new geographic markets represents a significant growth opportunity for Axonics. The company is currently focused on the United States, Europe, and select international markets. Expanding into Asia-Pacific and Latin America could drive substantial revenue growth. These regions have a large population base and increasing healthcare spending. The timeline for this expansion is ongoing, with the company actively evaluating opportunities in these markets. Success in these new markets will depend on regulatory approvals, market access, and effective distribution strategies.
• Increasing awareness of sacral neuromodulation (SNM) therapy among patients and healthcare providers is a key growth driver for Axonics. Many patients with bladder and bowel dysfunction are unaware of SNM as a treatment option. The company can invest in marketing and education initiatives to increase awareness and drive adoption. This includes educating physicians, participating in medical conferences, and engaging with patient advocacy groups. The timeline for this initiative is ongoing, with continuous efforts to raise awareness and promote SNM therapy. Increased awareness will lead to greater demand for Axonics' products and services.
• Development of new applications for SNM technology represents a significant growth opportunity for Axonics. The company is currently focused on bladder and bowel dysfunction, but SNM has the potential to treat other conditions, such as chronic pain and movement disorders. Investing in research and development to explore these new applications could expand the company's market reach and create new revenue streams. The timeline for this initiative is long-term, with ongoing research and clinical trials to evaluate the efficacy of SNM in these new areas. Successful development of new applications will position Axonics as a leader in the neuromodulation market.
• Strategic partnerships and collaborations can accelerate Axonics' growth and expand its market reach. Partnering with other medical device companies, healthcare providers, and research institutions can provide access to new technologies, markets, and expertise. This includes co-marketing agreements, joint product development, and licensing agreements. The timeline for this initiative is ongoing, with the company actively seeking strategic partnerships to enhance its capabilities and expand its market presence. Successful partnerships will drive revenue growth and strengthen Axonics' competitive position.
• Continued innovation in SNM technology is essential for Axonics to maintain its competitive advantage. The company must invest in research and development to improve its existing products and develop new technologies. This includes improving the battery life of its rechargeable SNM system, developing smaller and more comfortable devices, and exploring new stimulation parameters. The timeline for this initiative is ongoing, with continuous efforts to innovate and improve SNM technology. Successful innovation will differentiate Axonics from its competitors and drive long-term growth.

What Are AXNX's Competitive Advantages?

• Proprietary rechargeable SNM system offers a competitive advantage.
• Strong intellectual property protection for its SNM technology.
• Established relationships with key opinion leaders and healthcare providers.
• Direct salesforce and distribution network provide access to key markets.

What Does AXNX Do?

Axonics, Inc., founded in 2012 and based in Irvine, California, is a medical technology company focused on developing and commercializing innovative sacral neuromodulation (SNM) solutions. The company's primary focus is on addressing the unmet needs of patients suffering from bladder and bowel dysfunction. Axonics' flagship product is its proprietary rechargeable SNM (r-SNM) system. This system delivers mild electrical pulses to the sacral nerve, which helps to restore normal communication between the brain and the bladder and bowel, thereby reducing symptoms of overactive bladder (including urinary urge incontinence and urinary urgency frequency), fecal incontinence, and non-obstructive urinary retention. In addition to its r-SNM system, Axonics offers Bulkamid, a urethral bulking agent used to treat female stress urinary incontinence. Bulkamid provides a minimally invasive option for women seeking relief from this condition. Axonics sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and other international markets. The company's commitment to innovation and patient care has established it as a key player in the neuromodulation market.

What Products and Services Does AXNX Offer?

• Develop and commercialize sacral neuromodulation (SNM) systems.
• Offer a rechargeable SNM system for treating bladder and bowel dysfunction.
• Provide solutions for overactive bladder, urinary urge incontinence, and urinary urgency frequency.
• Treat fecal incontinence and non-obstructive urinary retention.
• Offer Bulkamid, a urethral bulking agent for female stress urinary incontinence.
• Sell products through a direct salesforce and distributors.
• Operate in the United States, the United Kingdom, Germany, the Netherlands, and Nordic countries.

How Does AXNX Make Money?

• Develop, manufacture, and sell sacral neuromodulation (SNM) systems.
• Generate revenue from the sale of SNM systems and related accessories.
• Offer Bulkamid, a urethral bulking agent, generating additional revenue.
• Utilize a direct salesforce and distributors to reach customers.

What Industry Does AXNX Operate In?

Axonics, Inc. operates in the medical device industry, specifically within the neuromodulation market. This market is characterized by increasing demand for minimally invasive therapies for chronic conditions. The competitive landscape includes established medical device companies and emerging players. Axonics differentiates itself through its rechargeable SNM technology and focus on patient comfort and convenience. The global neuromodulation market is expected to continue to grow, driven by an aging population and increasing prevalence of bladder and bowel dysfunction.

Who Are AXNX's Key Customers?

• Patients with overactive bladder, urinary urge incontinence, and urinary urgency frequency.
• Patients with fecal incontinence and non-obstructive urinary retention.
• Women with stress urinary incontinence.
• Hospitals and clinics that provide treatment for bladder and bowel dysfunction.

Axonics, Inc. (AXNX) Valuation Context

Valued at $3.63B, AXNX is classified as a mid-cap stock.

AXNX Revenue & Earnings Trend

In Q3 FY2024, AXNX generated $116.2M in top-line revenue, marking a sequential increase of 1.4%. The company recorded a net loss of $21K, with diluted EPS of $-0.00. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this mid-cap Healthcare company.

Company Profile

Axonics, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Irvine, US. The company is led by CEO Raymond W. Cohen. AXNX has traded publicly since 2018.

Return on equity for Axonics, Inc. stands at -1.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -0.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 10.73 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.2%, the inverse of the P/E and a quick read on earnings relative to price.

Axonics, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 20.38 places it in the safe zone, indicating low near-term bankruptcy risk.

Axonics, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 17.1% below estimates on average.

Wall Street analysts project Axonics, Inc. revenue of about $640.1M for fiscal 2026, with EPS near $1.20. The estimate reflects 8 contributing analysts.

The most recent 12 insider filings for Axonics, Inc. break down as 12 sales and 0 purchases. On net that is roughly 178K shares disposed (about $8.9M), a signal worth weighing alongside the fundamentals.

AXNX Financials

AXNX Latest News

What Investors Ask About Axonics, Inc. (AXNX) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources